1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
KPC Pharmaceuticals, Inc.

KPC Pharmaceuticals, Inc.

600422.SS
KPC Pharmaceuticals, Inc.CN flagShanghai Stock Exchange
8.88
CNY
-0.23
- -
6.72BMarket Cap
KPC Pharmaceuticals, Inc.
600422.SS
(Shanghai Stock Exchange)

Recent

price

8.88

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.89
3.87
4.8
5.51
5.47
6.23
6.47
7.45
9.24
10.66
10.17
10.89
11.02
11.07
11.15
8.64
5.9
Revenue per Share
0.14
0.21
0.29
0.36
0.37
0.53
0.52
0.42
0.44
0.6
0.6
0.67
0.51
0.71
0.86
0.46
0.06
Basic EPS, GAAP
0.04
0.15
0.14
0.05
0.22
0.34
0.14
0.02
0.18
0.11
0.33
0.02
0.2
0.85
0.97
0.26
-0.1
Free Cash Flow per Basic Share
0.04
0.09
0.12
0.16
0.18
0.09
0.23
0.21
0.06
0.15
0.24
0.27
0.31
0.19
0.23
0.37
0.06
Dividend per Share
0.77
0.88
1.05
1.24
1.23
1.71
2.48
2.7
3.13
3.62
3.99
4.38
4.62
5.08
5.78
5.9
5.83
Book Value per Share
1.12
1.26
1.25
2.46
2.41
3.72
3.92
3.98
4.25
4.75
5.19
5.6
6.02
7.61
6.12
6.33
6.25
Tangible Book Value per Share
628
628
628
651
789
789
789
786
769
761
759
758
751
762
754
761
746
Basic Weighted Avg Shares
1,817
2,434
3,016
3,584
4,316
4,916
5,101
5,852
7,102
8,120
7,717
8,254
8,282
8,430
8,401
6,575
4,403
Sales/Revenue/Turnover
7.13
7.35
7.84
8.09
7.9
9.84
7.97
7.54
6.09
6.89
7.06
6.98
7.42
10.56
11.74
5.71
1.91
Operating Margin (%)
36
36
43
45
70
77
81
95
100
124
151
184
209
209
199
193
- -
Depreciation Expense
86
130
182
232
289
421
407
330
336
454
457
508
383
541
648
350
47
Net Income, GAAP
15.92
16.95
16.86
16.92
16.65
14.75
14.85
17.81
18.09
14.08
14.49
18.7
19.24
18.27
19.62
11.51
18.29
Effective Tax Rate (%)
4.71
5.35
6.03
6.46
6.69
8.56
7.98
5.64
4.72
5.59
5.92
6.15
4.63
6.41
7.71
5.32
1.06
Profit Margin (%)
403
450
468
1,102
1,046
1,837
2,008
2,018
2,035
2,024
2,411
2,695
2,878
4,283
3,064
3,898
3,712
Working Capital
20
10
22
- -
- -
298
298
339
255
67
168
150
105
152
95
737
741
LT Debt
820
918
1,057
1,879
2,271
3,336
3,612
3,774
3,949
4,334
4,603
4,940
5,143
7,954
6,746
6,941
6,798
Total Equity
13.14
16.18
17.9
15.73
13.29
13.27
8.86
8.53
7.77
10.03
9.02
8.4
8.29
9.67
9.7
4.16
0.8
Return on Invested Capital (%)
11.77
16.35
18.65
24.37
24.38
26.82
19.54
12.88
11.91
14.15
12.72
12.75
9.12
8.35
8.81
4.51
0.57
Return on Capital (%)
19.03
25.07
29.85
31.52
32.53
36.3
24.62
16.18
14.83
17.62
15.81
15.99
11.28
14.72
15.75
7.91
1.06
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
949
874
LT Borrowings
- -
683
693
LT Finance Leases
- -
53
48
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
757
757
Market Capitalization
10,526
9,470
8,507

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
7,724
7,124
Cash, Cash Equivalents & STI
- -
2,344
1,624
Accounts Receivable, Net
- -
3,364
3,377
Inventories
- -
1,383
1,513
Total Current Liabilities
- -
3,826
3,412
Payables & Accruals
- -
- -
- -
ST Debt
- -
949
874
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.72%
10.76%
2.89%
Free Cash Flow
194%
210.92%
-72.73%
Net Income, GAAP
1.7%
0.31%
-46%
Sales/Revenue/Turnover
3.62%
-2.6%
-21.74%
Total Cash Common Dividend
34.4%
13.93%
62.31%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,927
1,702
1,903
2,944
8,401
2025
1,608
1,743
- -
1,824
6,575
2026
836
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
- -
- -
- -
0.86
2025
0.12
- -
- -
- -
0.46
2026
-0.19
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.23
2025
0.01
- -
- -
- -
0.37
2026
0.01
- -
- -
- -
- -
Similar Companies
Maywufa Company Ltd. (1731.TW)
Jinling Pharmaceutical Company Limited (000919.SZ)
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ)
Viatris Inc. (VTRS)
Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
Business
KPC Pharmaceuticals, Inc., a prominent drug manufacturer, is actively engaged in the research, development, production, and widespread distribution of pharmaceutical products within the People's Republic of China and across international markets. The company specializes in innovative natural botanical medicines, traditional Chinese remedies, and chemical pharmaceuticals, encompassing a broad range of drug circulation activities. Its comprehensive product portfolio features the Artemether series, crucial for malaria treatment, alongside the Panax Notoginseng and Gastrodine series, primarily targeting cardio-cerebral-vascular and nervous system disorders. Brands such as Luotai, Tianxuanqing, Artemedine, Artem, and Arco are well-regarded both domestically and internationally. Beyond these core offerings, KPC Pharmaceuticals also provides ethnic medicines, various antibiotics, essential chemical pharmaceutical raw materials, finished chemical preparations, traditional Chinese medicinal ingredients, biological agents, biochemical drugs, and health food items. The company’s strategic focus extends to chronic disease management and the burgeoning "silver age" health industry, leveraging Yunnan's rich plant resources to develop over 40 natural botanical drugs. Notably, its "777" brand centers on the Panax notoginseng series, and it holds a significant market share in Gastrodin products with the Tianxuanqing brand. KPC also champions artemisinin antimalarials globally, particularly in Africa, overseeing the entire value chain from cultivation to distribution. The enterprise, which originated as Kunming Pharmaceutical Corporation and adopted its current name in April 2015, was established in 1951 and maintains its headquarters in Kunming, China. It was listed on the Shanghai Stock Exchange in 2000 and currently operates numerous subsidiaries, distributing products in over 60 countries.